STAT3 and B-cell chronic lymphocytic leukemia: Since the levels of IL-6, one of the main activator of JAK2/STAT3 pathway, are significantly increased in serum of CLL patients and correlate with adverse clinical features and shorter survival [39], it is not surprising that we found higher P-STAT3-Tyr705 in patients with progressive disease requiring treatment.